Dark Pharma · DP-032
WE RAISED IT NINE TIMES. THE FDA APPROVED ZERO DESIGN CHANGES. EACH INCREASE WAS MODELLED AGAINST CUSTOMER DESPERATION.
Between 2009 and 2016, the LifeGuard epinephrine auto-injector’s price soared from $103 to $612, despite no changes to its design or formulation. The pricing committee’s decisions were based on families' desperation, leading to significant financial strain on parents.
Case Assets
The Case Debrief is free to view. Full Case Study, Teaching Notes, Slide Deck, Discussion Guide, and Assessment are available with a Premium subscription.
Brief the Board
PREMIUM
🔒 Unlock
Learn the Case
FREE — included
Study the Case
PREMIUM
🔒 Unlock
Teach the Case
PREMIUM
🔒 Unlock
Present the Case
PREMIUM
🔒 Unlock
Run a Team Discussion
PREMIUM
🔒 Unlock
Test Your Judgement
PREMIUM
🔒 Unlock
Watch the Full Episode
The complete cinematic audio documentary — Dark Pharma
Unlock the Full Case Library
Get every Case Study, Slide Deck, Teaching Notes, Discussion Guide, and Assessment — across a growing library of business cases.
View Pricing →Related Cases
Cases that share a governance or behavioural model with this one.
Dark Law
DL-038
He Warned Them The Bank Was Taking On Too Much Risk. They Fired Him Wi...
Shared: Independent Oversight Committee
B-School Noir
BN-035
He Ghostwrote The Applications. The Students Never Knew What Was In Th...
Shared: Independent Oversight Committee
Dark Law
DL-033
SHE TESTIFIED ON JUNE 11, 2015. THE COMMISSIONER RULED IN HER FAVOUR. ...
Shared: Stakeholder Engagement Model
Sovereign Games
SG-042
HE GOT THE CALL ON TUESDAY FROM SAXONWOLD. THE APPOINTMENT CAME THURSD...
Shared: Independent Oversight Committee